Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramucirumab PK interaction with FOLFIRI in solid tumors
NCT01634555Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2012
- Primary completion
- Aug 2013
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ramucirumab in solid tumor, sponsored by Eli Lilly and Company. Started Oct 2012; status: completed.
02
Drugs
ramucirumab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT01634555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01634555.